Gene therapy aims to calm overactive bladder for years with one shot
Disease control
Not yet recruiting
This study follows 16 people who already received EG110A, a gene therapy that uses a modified herpes virus to deliver a botulinum toxin-like protein to relax bladder muscles. Researchers will track side effects and how well the treatment works over five years. The goal is to see …
Phase: PHASE1, PHASE2 • Sponsor: EG 427 • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC